GLP-1 Cardiometabolic Safety & Optimization Panel
- $1,570.88
- $398
- Save: 74.66%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Microalbumin Random Urine with Creatinine
Creatinine, Random Urine
Microalbumin
Microalbumin/Creatinine
Amylase
Also known as: Apolipoprotein B Cardio IQ, Cardio IQ Apolipoprotein B
Apolipoprotein B
Also known as: Bilirubin Direct, Conjugated Bilirubin
Bilirubin, Direct
Also known as: Bilirubin Fractionated
Bilirubin, Indirect
Bilirubin, Total
Also known as: C-Terminal Insulin, Connecting peptide insulin, CPeptide, Insulin C-peptide, Proinsulin C-peptide
C-Peptide
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Also known as: CK (Total), CPK, CPK (Total), Creatine Kinase CK Total, Creatine Phosphokinase (CPK), Total CK
Creatine Kinase, Total
Ferritin
Also known as: Gamma Glutamyl Transferase GGT, Gamma-Glutamyl Transferase, Gamma-Glutamyl Transpeptidase, Gamma-GT, GGTP, GTP
Ggt
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
HEMOGLOBIN A1C
Also known as: Homocysteine, Homocysteine Cardiovascular
HOMOCYSTEINE,
Also known as: C-Reactive Protein, Cardio CRP, Cardio hs-CRP, CRP, High Sensitivity CRP, High-sensitivity C-reactive Protein, High-sensitivity CRP, Highly Sensitive CRP, hsCRP, Ultra-sensitive CRP
Hs Crp
Also known as: Insulin (fasting)
Insulin
Also known as: LPS
Lipase
Also known as: Cardio IQ Lipid Panel, Cholesterol and Lipids, Lipid Panel Cardio IQ, Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
Non HDL Cholesterol
Triglycerides
Also known as: Ion Mobility, Cardio IQ Lipoprotein Fractionation, Ion Mobility , HDL Subfractions, IDL Subfractions, LDL Subfractions, Lipoprotein Fraction, Lipoprotein Fractionation, Lipoprotein Fractionation Ion Mobility Cardio IQ, Quest Diagnostics has replaced the VAP® Cholesterol Test with Lipoprotein Fractionation, Ion Mobility, Cardio IQ™ test
HDL Large
LDL Medium
LDL Particle Number
LDL Pattern
LDL Peak Size
LDL Small
Also known as: Magnesium RBC
Magnesium, Rbc
The GLP-1 Cardiometabolic Safety & Optimization Panel panel contains 18 tests with 51 biomarkers .
GLP-1 Side Effect Monitoring Panel
Advanced Safety & Cardiometabolic Impact Testing for GLP-1 Medications
GLP-1 medications such as semaglutide and tirzepatide are powerful tools for weight loss and metabolic improvement — but they also change how your body processes glucose, fat, liver enzymes, and pancreatic activity.
The GLP-1 Side Effect Monitoring Panel is designed to establish a baseline and monitor key biomarkers that may shift during therapy. This comprehensive panel helps detect early changes in kidney function, liver health, pancreatic enzymes, lipid particle patterns, muscle integrity, and cardiometabolic risk markers — allowing you and your healthcare provider to optimize therapy safely.
Why This Panel Matters
GLP-1 medications can affect:
• Kidney function (especially during dehydration)
• Pancreatic enzymes
• Gallbladder and biliary markers
• Lipid metabolism and particle size
• Insulin production and sensitivity
• Muscle integrity (if used alongside statins)
• Inflammation and vascular risk
Monitoring these markers helps distinguish normal metabolic improvement from potential safety concerns.
What This Panel Measures
Kidney Function & Hydration Protection
Comprehensive Metabolic Panel (CMP)
Why included for GLP-1 therapy:
GLP-1 medications commonly cause nausea, vomiting, reduced appetite, and decreased fluid intake.
Detects:
-
Creatinine and eGFR changes
-
Electrolyte shifts (sodium, potassium, CO2)
-
Baseline glucose
Monitors:
-
Dehydration-related kidney stress
-
Electrolyte imbalance during GI side effects
-
Renal safety during dose escalation
Alerts to:
-
Acute kidney injury
-
Significant electrolyte disturbances
Protects by:
Identifying kidney stress early — especially in patients on diuretics, ACE inhibitors, or with pre-existing CKD.
Albumin, Random Urine with Creatinine (uACR)
Why included:
Improved glycemic control can change glomerular filtration dynamics.
Detects:
-
Microalbuminuria
Monitors:
-
Early kidney stress
Alerts to:
-
Early diabetic or hypertensive nephropathy
Protects by:
Detecting renal damage before serum creatinine rises.
Liver & Gallbladder Monitoring (via CMP + Bilirubin + GGT)
Rapid weight loss associated with GLP-1 therapy increases gallstone risk.
Comprehensive Metabolic Panel (CMP – liver components)
Why included for liver monitoring:
CMP includes ALT, AST, alkaline phosphatase (ALP), total bilirubin, albumin, and total protein.
Detects:
-
Hepatocellular enzyme elevation (ALT/AST)
-
Cholestatic pattern (ALP elevation)
-
Total bilirubin elevation
Monitors:
-
Liver enzyme changes during therapy
-
Gallbladder-related biochemical shifts
Alerts to:
-
Drug-induced liver injury
-
Biliary obstruction patterns
Protects by:
Providing a broad hepatic safety screen without redundant testing.
Bilirubin, Direct & Fractionated
Why included:
If total bilirubin rises on CMP, fractionation clarifies cause.
Detects:
-
Conjugated vs. unconjugated elevation
Monitors:
-
Biliary flow patterns
Alerts to:
-
Gallstones or bile duct obstruction during rapid weight loss
Protects by:
Guiding imaging and further evaluation when necessary.
Gamma Glutamyl Transferase (GGT)
Why included:
GGT strengthens detection of biliary-related issues when ALP is elevated.
Detects:
-
Early cholestatic or gallbladder patterns
Monitors:
-
Biliary stress
Alerts to:
-
Gallbladder involvement
Protects by:
Improving detection specificity when paired with ALP and bilirubin.
Pancreatic Safety Monitoring
Lipase
Why included:
Primary enzyme used to evaluate suspected pancreatitis.
Detects:
-
Pancreatic inflammation
Monitors:
-
Enzyme changes if abdominal symptoms occur
Alerts to:
-
Acute pancreatitis
Protects by:
Supporting rapid clinical evaluation if symptoms arise.
Amylase
Why included:
Supportive pancreatic enzyme marker.
Detects:
-
Pancreatic irritation
Monitors:
-
Trends alongside lipase
Alerts to:
-
Early enzyme elevation
Protects by:
Adding confirmatory data in symptom-driven evaluation.
Glucose & Insulin Regulation
GLP-1 therapy improves insulin sensitivity and glucose control.
Hemoglobin A1c (HgbA1c)
Detects: Long-term glycemic improvement
Monitors: 2–3 month glucose trends
Alerts to: Hypoglycemia risk if combined with insulin/sulfonylureas
Protects by: Guiding medication adjustment
Insulin
Detects: Hyperinsulinemia
Monitors: Insulin resistance improvement
Alerts to: Persistent insulin resistance
Protects by: Supporting metabolic optimization
C-Peptide
Detects: Endogenous insulin production
Monitors: Beta-cell function
Alerts to: Declining pancreatic function
Protects by: Clarifying metabolic response patterns
Advanced Cardiovascular Risk Monitoring
GLP-1 therapy often improves lipid and inflammatory markers.
Lipid Panel, Cardio IQ™
Tracks LDL, HDL, and triglyceride changes during weight loss.
Apolipoprotein B
Measures total atherogenic particle burden.
Lipoprotein Fractionation, Ion Mobility
Evaluates LDL particle size and number.
hs-CRP
Monitors systemic inflammation and vascular risk.
Homocysteine
Identifies additional endothelial risk beyond cholesterol.
These markers ensure cardiovascular improvements align with weight loss progress.
Muscle & Nutrient Monitoring
Creatine Kinase (CK), Total
Monitors muscle injury risk — particularly if combined with statins.
Ferritin
Evaluates iron stores and inflammation during caloric restriction.
Magnesium, RBC
Detects intracellular magnesium depletion from dehydration or reduced intake.
Summary
This panel uses the CMP as the central safety anchor to evaluate kidney and liver function, while adding targeted markers to monitor:
• Pancreatic safety
• Gallbladder risk
• Glucose and insulin dynamics
• Lipid particle improvements
• Inflammatory status
• Muscle integrity
• Nutrient balance
It provides comprehensive oversight — supporting safe, optimized GLP-1 therapy.
When to Test
• Before starting GLP-1 therapy (baseline)
• 8–12 weeks after dose escalation
• If experiencing persistent nausea, abdominal pain, or fatigue
• Every 3–6 months during active therapy
Preparation Instructions
• Fast 8–12 hours prior to blood draw
• Stay well hydrated
• Continue medications unless instructed otherwise by your provider
Who Should Consider This Panel
-
Individuals using semaglutide or tirzepatide
-
Patients combining GLP-1 therapy with statins or antihypertensives
-
Individuals with a history of gallbladder disease
-
Patients seeking comprehensive metabolic optimization
Optimize Results. Monitor Safety. Stay In Control.
The GLP-1 Side Effect Monitoring Panel delivers advanced insight into how your body is responding — helping you achieve metabolic progress with confidence.